Product Description: Pargyline hydrochloride is an irreversible monoamine oxidase (MAO) inhibitor with Kis of 13 μM and 0.5 μM for MAO-A and MAO-B, respectively. Pargyline hydrochloride has antihypertensive and anticancer activities[1][2][3]. Pargyline (hydrochloride) is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
Applications: COVID-19-immunoregulation
Formula: C11H14ClN
Citations: Parkinsons Dis-us. 2022./J Parkinson Dis. 2020;10(2):523-542./Neural Regen Res. 2021;16:1660-70.
References: [1]C J Fowler, et al. The nature of the inhibition of rat liver monoamine oxidase types A and B by the acetylenic inhibitors clorgyline, l-deprenyl and pargyline. Biochem Pharmacol. 1982 Nov 15;31(22):3555-61./[2]Fuentes JA, et al. Central mediation of the antihypertensive effect of pargyline in spontaneously hypertensive rats. Eur J Pharmacol. 1979 Jul 15;57(1):21-7./[3]Hyung Tae Lee, et al. Effects of the monoamine oxidase inhibitors pargyline and tranylcypromine on cellular proliferation in human prostate cancer cells. Oncol Rep. 2013 Oct;30(4):1587-92.
CAS Number: 306-07-0
Molecular Weight: 195.69
Compound Purity: 99.91
Research Area: Cancer; Cardiovascular Disease
Solubility: DMSO : 125 mg/mL (ultrasonic)/H2O : 100 mg/mL (ultrasonic)
Target: Monoamine Oxidase
English
Deutsch
